PRME · Company research
Prime Medicine, Inc. Common Stock (PRME): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Prime Medicine, Inc. (PRME) - What Are Brokerages Thinking About This Stock? - MarketBeat | Prime Medicine, Inc. (PRME) - What Are Brokerages Thinking About This Stock? MarketBeat | View source ↗ | MarketBeat | Oct 17, 2026 | neutral | 0 | 0.6 |
| Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade | Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ StocksToTrade | View source ↗ | StocksToTrade | Oct 17, 2026 | neutral | 0 | 0.6 |
| Prime Drink Group Corp. (PRME.CN) Stock Price, News, Quote & History - Yahoo! Finance Canada | Prime Drink Group Corp. (PRME.CN) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| Prime Medicine (NASDAQ:PRME) Stock Jumps 8.5% - Time to Buy? - MarketBeat | Prime Medicine (NASDAQ:PRME) Stock Jumps 8.5% - Time to Buy? MarketBeat | View source ↗ | MarketBeat | Oct 15, 2026 | neutral | 0 | 0.6 |
| First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history - Yahoo Finance UK | First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 13, 2026 | neutral | 0 | 0.6 |
| Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History - Yahoo! Finance Canada | Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 13, 2026 | neutral | 0 | 0.6 |
| Prime Medicine, Inc. (PRME) stock price, news, quote and history - Yahoo Finance Singapore | Prime Medicine, Inc. (PRME) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 12, 2026 | neutral | 0 | 0.6 |
| Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - TradingView | Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why TradingView | View source ↗ | TradingView | Oct 12, 2026 | neutral | 0 | 0.6 |
| Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why | Prime Medicine (PRME) has achieved significant regulatory and clinical progress, receiving FDA clearance for PM647 targeting alpha-1 antitrypsin deficiency and dosing the first patient in a phase I/II trial of PM577a for Wilson disease. The stock has gained 26% over the past month, outperforming the biotech industry's 2.8% decline, driven by these encouraging developments in its Prime Editing platform for genetic disease treatments. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.4 | 1 |
| PRME 261016 6.00P (PRME261016P6000) Stock Options Chain | Quotes & News - Moomoo | PRME 261016 6.00P (PRME261016P6000) Stock Options Chain | Quotes & News Moomoo | View source ↗ | Moomoo | Oct 12, 2026 | neutral | 0 | 0.6 |
| CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks? - Stocktwits | CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks? Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| Prime Medicine (PRME) Short Interest & Short Float | Updated Oct 2026 - MarketBeat | Prime Medicine (PRME) Short Interest & Short Float | Updated Oct 2026 MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| Prime Medicine (NASDAQ:PRME) Stock Falls 7.6% - Here's Why - MarketBeat | Prime Medicine (NASDAQ:PRME) Stock Falls 7.6% - Here's Why MarketBeat | View source ↗ | MarketBeat | Oct 8, 2026 | neutral | 0 | 0.6 |
| Prime Medicine (PRME) Stock Draws Traders On FDA Trial Wins - Timothy Sykes | Prime Medicine (PRME) Stock Draws Traders On FDA Trial Wins Timothy Sykes | View source ↗ | Timothy Sykes | Oct 6, 2026 | neutral | 0 | 0.6 |
| Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | Prime Medicine announced the first patient dosing in its Phase 1/2 clinical trial of PM577a, an in vivo Prime Editor therapy for H1069Q-mutated Wilson disease. The FDA granted Rare Pediatric Disease designation to PM577, and the company expects initial clinical data in 2027. PM577a is designed as a one-time curative therapy targeting the most prevalent Wilson disease-causing mutation in North America and Europe. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bullish | 1 | 1 |
| Prime Medicine (NasdaqGM:PRME) Stock Forecast & Analyst Predictions - Simply Wall Street | Prime Medicine (NasdaqGM:PRME) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 5, 2026 | neutral | 0 | 0.6 |
| PRME Stock Dips As Prime Medicine Faces Steep Losses - StocksToTrade | PRME Stock Dips As Prime Medicine Faces Steep Losses StocksToTrade | View source ↗ | StocksToTrade | Sep 25, 2026 | neutral | 0 | 0.6 |
| FDA clears testing of a genetic treatment aimed at a variant carried by about 100,000 people in the U.S. - Stock Titan | FDA clears testing of a genetic treatment aimed at a variant carried by about 100,000 people in the U.S. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| Prime Medicine: Soon In The Clinic (NASDAQ:PRME) - Seeking Alpha | Prime Medicine: Soon In The Clinic (NASDAQ:PRME) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 15, 2026 | neutral | 0 | 0.6 |
| Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - Yahoo Finance | Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Yahoo Finance | View source ↗ | Yahoo Finance | Jul 30, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.